BANGSHUN PHARMA HKEX IPO Application Lapses, No Commercialised Products Yet
NewTimeSpace News: The listing application of Hangzhou Bangshun Pharmaceutical Co., Ltd. submitted to HKEX on 22 January 2026 has lapsed upon expiry of the six-month validity period. China Securities International served as the original sole sponsor. The Company is a biotech firm nearing commercialisation, focusing on oncology and autoimmune diseases. Its core asset Bezacitinib is expected to become one of the first three domestically developed JAK inhibitors approved in China, ranking No.1 in clinical progress nationwide for the indication of polycythemia vera.
NewTimeSpace News: The listing application submitted by Hangzhou Bangshun Pharmaceutical Co., Ltd. to The Stock Exchange of Hong Kong Limited on 22 January 2026 has lapsed following the expiration of the six-month validity term. China Securities International acted as the original sole sponsor.
The Company is a clinical-stage biotech enterprise approaching commercial launch, concentrating on oncology and autoimmune diseases, and committed to translating scientific discoveries into accessible innovative therapies for patients. It strategically focuses on developing highly differentiated oral small-molecule drug candidates to address substantial unmet clinical needs in haematological malignancies and autoimmune disorders.
Leveraging its proprietary high-selectivity small-molecule drug discovery platform and molecular glue discovery platform, the Company has built a pipeline covering one NDA-stage candidate (Bezacitinib), one candidate under registrational clinical trials (CX1440) and five pre-clinical assets.
According to Frost & Sullivan data as of the latest practicable date, core product Bezacitinib is expected to be among the first three domestically developed JAK inhibitors approved in China for myelofibrosis treatment. In terms of clinical advancement, Bezacitinib ranks first among Chinese JAK inhibitors for polycythemia vera and leads globally among JAK inhibitors targeting essential thrombocythemia. Another core candidate CX1440 ranks among the world’s top three BTK inhibitors for immune thrombocytopenic purpura, and within the global top two BTK candidates for chronic spontaneous urticaria and autoimmune hemolytic anemia.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- HKIC Portfolio Company StepFun Launches STEPX, the World's First LLM-Native AI Terminal Brand, Completing a Full-Stack AI Ecosystem
- SHANGHAI A&I CO., LTD.: HKEX IPO Application Lapses, a Leading Provider of Integrated Intelligent Manufacturing System Solutions in China
- Csop Samsung Electronics Daily (2x) Leveraged Product (07747.HK) Rises 1.32% in Afternoon Trade, Turnover at HKD 1.359 Billion
- Autonomous Driving Concept Stocks Watch | XPENG-W(09868.HK) Trades Weakly and Volatile in Afternoon Session; TuringViT Efficient Vision Encoder Officially Launched
- Ping An of China CSI HK Dividend ETF(03070.HK) Rises 0.35% Intraday, Assets Under Management Reach HK$1.449 Billion
